Table 1.

Selected studies with preliminary or final results using the combination of ICIs and antiangiogenesis

Antiangiogenesis drugTargetICI drugTargetSample size (N)Tumor typeClinical activityCorrelatives
BevacizumabVEGF-AIpilimumabCTLA-446MelanomaORR 32% DCR 64% OS 25 monthsIncrease infiltration of T cells and macrophages (CD163+). Increase circulating memory cells (CD45R0) (43)
BevacizumabVEGF-AAtezolizumabPD-L1101RCCORR 32% PFS 11.7 monthsImproved outcomes in tumors with immune-suppressed gene signature (44)
Bevacizumab + carboplatin + paclitaxelVEGF-AAtezolizumabPD-L1356NSCLCORR 63% PFS 8.3 months OS 11.3 monthsSubgroups with low PD-L1 and T-effector gene signature benefited (46)
BevacizumabVEGF-AAtezolizumabPD-L1101HCCORR 62%(47)
AxitinibVEGFR1-3PembrolizumabPD-121RCCORR 38% PFS 21 months(48, 49)
AxitinibVEGFR1-3AvelumabPD-L1356RCCORR 58%(50, 51)
SunitinibVEGFR1-3NivolumabPD-155RCCORR 55% PFS 12.7 months(53)
PazopanibVEGFR1-3NivolumabPD-152RCCORR 45% PFS 7.2 months(53)
  • Abbreviations: DCR, disease control rate; HCC, hepatocellular carcinoma; NSCLC, non–small cell lung cancer; ORR, overall response rate; OS, overall survival; PFS, progression-free survival.